Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 1.00 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL30800725 | 0.98 | LTA4H (0.96) | LTA4HCYP17A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL30800724 | 0.89 | LTA4H (0.79) | LTA4HCYP17A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL30800723 | 0.89 | LTA4H (0.79) | LTA4HCYP17A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL30800726 | 0.89 | LTA4H (0.79) | LTA4HCYP17A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL111078 | 0.84 | LTA4H (0.72) | LTA4HCYP17A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL338810 | 0.83 | LTA4H (0.70) | LTA4HCYP17A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL7455134 | 0.81 | LTA4H (0.67) | LTA4HCYP17A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL404521 | 0.81 | LTA4H (0.68) | LTA4HCYP17A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL8340210 | 0.81 | LTA4H (0.68) | LTA4HCYP17A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL1437852 | 0.81 | LTA4H (0.68) | LTA4HCYP17A1CYP11B1CYP11B2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117684274-A | Low-dimensional perovskite single crystal material and preparation method and application thereof | 南华大学 | 2024-03-12 | — | — | CN | claimed |
| WO-2025067540-A1 | PYRAZOLOTRIAZINE AND PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 中国科学院上海药物研究所 | 2025-04-03 | — | — | WO | disclosed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-117684274-A | Low-dimensional perovskite single crystal material and preparation method and application thereof | 南华大学 | 2024-03-12 | — | — | CN | disclosed |
| CN-117684274-A | Low-dimensional perovskite single crystal material and preparation method and application thereof | 南华大学 | 2024-03-12 | — | — | CN | disclosed |
| WO-2022109078-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-3325480-B1 | 5-SUBSTITUTED-7-[4-(SUBSTITUTED) BENZYL]AMINO-3-ISOPROPYLPYRAZOLO (4,3-D) PYRIMIDINES AS MEDICAMENTS | USTAV EXPERIMENTALNI BOTANIKY AV CR V V I (CZ) | 2020-04-22 | — | — | EP | disclosed |
| CN-109776537-A | Purinedione as WNT pathway modulators | 新加坡科技研究局 | 2019-05-21 | — | — | CN | disclosed |
| CN-1353713-A | Purine inhibitors of cyclin dependent kinase 2 and IK B-alpha | CV THERAPEUTICS INC (US) | 2002-06-12 | — | — | CN | disclosed |
| US-20020035252-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkBa | LUM ROBERT T (US) | 2002-03-21 | — | — | US | disclosed |
| US-20020032327-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkappaBalpha | CV THERAPEUTICS, INC. | 2002-03-14 | — | — | US | disclosed |
| EP-1150982-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND I$g(k)-A$g(a) | CV THERAPEUTICS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000044750-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a) | CV THERAPEUTICS, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-1021186-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-1021186-A4 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS INC (US) | 2000-07-26 | — | — | EP | disclosed |
| CN-1231611-A | Puring inhibitors of cylin dependent kinase 2 and I'kappa'beta-'alpha' | CV THERAPEUTIC INC (US) | 1999-10-13 | — | — | CN | disclosed |
| WO-1998005335-A9 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | — | 1998-05-28 | — | — | WO | disclosed |
| WO-1998005335-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | CV THERAPEUTICS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | LTA4H 2159/4885CYP17A1 2387/4885CYP11B1 858/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | LTA4H 2159/4885CYP17A1 2387/4885CYP11B1 858/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | LTA4H 2448/4885CYP17A1 2367/4885CYP11B1 835/4885 |
| US-20020032327-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkappaBalpha | CDKN1A, CCNK, CDK1 | LTA4H 3153/4885CYP17A1 4316/4885CYP11B1 3675/4885 |
| US-20020035252-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkBa | AURKB, CDKN1A, IKBKB | LTA4H 3338/4885CYP17A1 4177/4885CYP11B1 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.